BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 32341463)

  • 1. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets.
    Curran AM; Naik P; Giles JT; Darrah E
    Nat Rev Rheumatol; 2020 Jun; 16(6):301-315. PubMed ID: 32341463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis.
    Darrah E; Davis RL; Curran AM; Naik P; Chen R; Na CH; Giles JT; Andrade F
    Arthritis Rheumatol; 2020 Sep; 72(9):1476-1482. PubMed ID: 32255561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays.
    Poulsen TBG; Damgaard D; Jørgensen MM; Senolt L; Blackburn JM; Nielsen CH; Stensballe A
    Sci Rep; 2021 Aug; 11(1):17300. PubMed ID: 34453079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis.
    Lloyd KA; Wigerblad G; Sahlström P; Garimella MG; Chemin K; Steen J; Titcombe PJ; Marklein B; Zhou D; Stålesen R; Ossipova E; Lundqvist C; Ekwall O; Rönnelid J; Mueller DL; Karlsson MCI; Kaplan MJ; Skriner K; Klareskog L; Wermeling F; Malmström V; Grönwall C
    Front Immunol; 2018; 9():3033. PubMed ID: 30662440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine.
    Martinez-Prat L; Palterer B; Vitiello G; Parronchi P; Robinson WH; Mahler M
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1073-1087. PubMed ID: 31524005
    [No Abstract]   [Full Text] [Related]  

  • 6. Generation of Distinct Patterns of Rheumatoid Arthritis Autoantigens by Peptidylarginine Deiminase Types 2 and 4 During Perforin-Induced Cell Damage.
    Romero V; Darrah E; Andrade F
    Arthritis Rheumatol; 2020 Jun; 72(6):912-918. PubMed ID: 31876120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.
    Li B; Li P; Bi L
    Clin Rheumatol; 2020 Mar; 39(3):899-907. PubMed ID: 31758423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.
    Darrah E; Rosen A; Giles JT; Andrade F
    Ann Rheum Dis; 2012 Jan; 71(1):92-8. PubMed ID: 21859690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
    Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
    Front Immunol; 2018; 9():2696. PubMed ID: 30515171
    [No Abstract]   [Full Text] [Related]  

  • 10. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
    Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
    Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
    Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
    Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periodontal sources of citrullinated antigens and TLR agonists related to RA.
    Vitkov L; Hannig M; Minnich B; Herrmann M
    Autoimmunity; 2018 Sep; 51(6):304-309. PubMed ID: 30417696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.
    Damgaard D; Bawadekar M; Senolt L; Stensballe A; Shelef MA; Nielsen CH
    PLoS One; 2018; 13(8):e0203214. PubMed ID: 30161253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid.
    Spengler J; Lugonja B; Ytterberg AJ; Zubarev RA; Creese AJ; Pearson MJ; Grant MM; Milward M; Lundberg K; Buckley CD; Filer A; Raza K; Cooper PR; Chapple IL; Scheel-Toellner D
    Arthritis Rheumatol; 2015 Dec; 67(12):3135-45. PubMed ID: 26245941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
    Blachère NE; Parveen S; Frank MO; Dill BD; Molina H; Orange DE
    Arthritis Rheumatol; 2017 May; 69(5):986-995. PubMed ID: 28029744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.
    Bawadekar M; Shim D; Johnson CJ; Warner TF; Rebernick R; Damgaard D; Nielsen CH; Pruijn GJM; Nett JE; Shelef MA
    J Autoimmun; 2017 Jun; 80():39-47. PubMed ID: 28188029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4.
    Martín Monreal MT; Rebak AS; Massarenti L; Mondal S; Šenolt L; Ødum N; Nielsen ML; Thompson PR; Nielsen CH; Damgaard D
    Front Immunol; 2021; 12():716250. PubMed ID: 34737738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of PAD2- and PAD4-mediated protein citrullination catalysis in cancers.
    Wang Y; Chen R; Gan Y; Ying S
    Int J Cancer; 2021 Jan; 148(2):267-276. PubMed ID: 33459350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.
    Giles JT; Darrah E; Danoff S; Johnson C; Andrade F; Rosen A; Bathon JM
    PLoS One; 2014; 9(6):e98794. PubMed ID: 24901704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.
    Harris ML; Darrah E; Lam GK; Bartlett SJ; Giles JT; Grant AV; Gao P; Scott WW; El-Gabalawy H; Casciola-Rosen L; Barnes KC; Bathon JM; Rosen A
    Arthritis Rheum; 2008 Jul; 58(7):1958-67. PubMed ID: 18576335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.